Business Context and Reporting Period
This Form 6-K filing by Genenta Science S.P.A. covers the month of June 2026, specifically addressing a corporate event dated June 15, 2026. The Company is a foreign private issuer headquartered in Milan, Italy, with its American Depositary Shares (ADSs) listed on The Nasdaq Stock Market.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5550(a)(2). Previously, on April 10, 2026, the Company received notice of non-compliance because its ADS closing bid price remained below $1.00 per share for 30 consecutive business days. As of June 15, 2026, Nasdaq confirmed that the Company regained compliance after maintaining a closing bid price at or above $1.00 per share for 10 consecutive business days (June 1, 2026, through June 12, 2026).
Outlook and Risks
Nasdaq has formally notified the Company that the matter regarding the minimum bid price requirement is closed. The filing contains no management commentary on future financial guidance, operational outlook, or new risk factors beyond the resolution of the listing deficiency.
Key Facts for Investor Verification
- Genenta Science S.P.A. has regained compliance with the Nasdaq minimum bid price requirement of $1.00 per share.
- The compliance period was verified over 10 consecutive business days ending June 12, 2026.
- The prior deficiency notice issued on April 10, 2026, has been resolved and the matter is closed.
- No financial performance data is included in this specific filing.